About Paige AI
Paige applies the power of foundation models to cancer care, delivering models that set new standards for size, scale and performance in pathology.
Mission & Story
Mission
Revolutionizing pathology with next generation technology
Clinical Focus
Medical conditions and clinical areas addressed by Paige AI.
Who It Serves
Milestones & Awards
Recent Milestones
Launch of Paige Alba multi-modal co-pilot, Paige GI Suite built on latest foundation model technology, expansion of PanCancer Suite to 40+ tissue types, OmniScreen predicting 1,600+ biomarkers from H&E alone
Awards & Recognition
First FDA-approved AI in pathology, 3 FDA Breakthrough Device Designations, published in Nature Medicine
Key Partnerships
Social & Media
Follow on
Latest Updates
Paige and NHS Wales Launch PanCancer Pilot to Triage Cases with AI at Betsi Cadwaladr University Health Board
Burjeel Holdings Partners with US-Based Paige to Deploy FDA-Approved AI in Cancer Diagnostics Across MENA
Paige Releases PRISM2: A Whole-Slide Foundation Model for Multimodal AI in Pathology and Cancer Care
Sectra’s fully managed AI offering extended to include pathology following new Amplifier partner agreement
Paige Releases PRISM2: A Whole-Slide Foundation Model for Multimodal AI in Pathology and Cancer Care
Company Details
- Founded
- 2017
- Headquarters
- New York, NY, USA
- Employees
- 125
- Stage
- acquired
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.